UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2128-10
Program Prior Authorization/Medical Necessity
Medication Ibsrela® (tenapanor)*, Trulance® (plecanatide)*
P&T Approval Date 6/2017, 3/2018, 3/2019, 12/2019, 12/2020, 12/2021, 4/2022, 11/2022,
11/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Ibsrela (tenapanor)* is indicated for treatment of irritable bowel syndrome with constipation
(IBS-C) in adults. Amitiza® (lubiprostone)* is indicated for the treatment of IBS-C in women 18
years of age and older, chronic idiopathic constipation (CIC) in adults, and opioid-induced
constipation in adult patients with chronic, non-cancer pain, including patients with chronic pain
related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage
escalation. Linzess® (linaclotide) and Trulance® (plecanatide)* are indicated for the treatment of
CIC and for the treatment of adults with IBS-C; while, Motegrity® is indicated for the treatment
of CIC in adults. Physicians and patients should periodically assess the need for continued
treatment with Ibsrela*,Linzess, Motegrity or Trulance*.
This prior authorization program is intended to encourage the use of lower cost alternatives
before providing coverage for Ibsrela*and Trulance*.
2. Coverage Criteriaa:
A. Chronic Idiopathic Constipation
1. Initial Authorization
a. Trulance* will be approved based on both of the following criteria:
1) Diagnosis of chronic idiopathic constipation
- AND-
2) History of failure, contraindication, or intolerance to two of the following
(document drug and date tried):
a) lubiprostone (generic Amitiza)
b) Linzess
c) Motegrity
Authorization will be issued for 12 months
2. Reauthorization
a. Trulance* will be approved based on the following criterion:
© 2024 UnitedHealthcare Services Inc.
1
1) Documentation of positive clinical response to therapy
Authorization will be issued for 12 months
B. Irritable Bowel Syndrome with Constipation
1. Initial Authorization
a. Ibsrela* will be approved based on both of the following criteria:
1) Diagnosis of irritable bowel syndrome with constipation
-AND-
2) History of failure, contraindication, or intolerance to both of the following
(document date tried):
a) lubiprostone (generic Amitiza)
b) Linzess
Authorization will be issued for 12 months
b. Trulance* will be approved based on both of the following criteria:
1) Diagnosis of irritable bowel syndrome with constipation
-AND-
2) History of failure, contraindication, or intolerance to both of the following
(document date tried):
a) lubiprostone (generic Amitiza)
b) Linzess
Authorization will be issued for 12 months
2. Reauthorization
a. Ibsrela*or Trulance* will be approved based on the following criterion:
1) Documentation of positive clinical response to therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Ibsrela, Trulance and Brand Amitiza are typically excluded from coverage
© 2024 UnitedHealthcare Services Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• Notification/Prior Authorization may be in place
4. References:
1. Amitiza [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November
2020.
2. Ibsrela [package insert]. Waltham, MA: Ardelyx; April 2022.
3. Linzess [package insert]. North Chicago, IL: AbbVie, Inc; June 2023
4. Motegrity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November
2020
5. Trulance [package insert]. Bridgewater, NJ: Bausch Health US, LLC; March 2024.
Program Prior Authorization/Medical Necessity – Ibsrela (tenapanor), Trulance
(plecanatide)
Change Control
Date Change
6/2017 New program
3/2018 Added newly approved indication for irritable bowel syndrome with
constipation.
3/2019 Annual review. Modified documentation language, added statement
regarding use of automated process and updated references.
12/2019 Added Ibsrela and Zelnorm to criteria.
12/2020 Removed Ibsrela since noted as discontinued on FDA website.
Updated references.
12/2021 Annual review. Added a step through Motegrity for Trulance for CIC.
Added that Trulance is typically excluded form coverage.
4/2022 Added criteria for Ibsrela. Updated references.
11/2022 Zelnorm removed since discontinued from market. Updated references.
11/2023 Annual review. Removed OTC step requirement and added
lubiprostone. Updated references.
7/2024 Review. Added documentation requirement. Updated references.
© 2024 UnitedHealthcare Services Inc.
3